Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 11Terminated 3Unknown 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 697Urinary Bladder Neoplasms 256Carcinoma, Renal Cell 190Kidney Neoplasms 94Neoplasms 72Carcinoma, Transitional Cell 69Breast Neoplasms 66Lung Neoplasms 38Ovarian Neoplasms 37Melanoma 37Colorectal Neoplasms 37Stomach Neoplasms 36Non-Muscle Invasive Bladder Neoplasms 35Neoplasm Metastasis 33Pancreatic Neoplasms 31Carcinoma, Non-Small-Cell Lung 29Recurrence 26Colonic Neoplasms 25Uterine Cervical Neoplasms 20Urologic Neoplasms 20Testicular Neoplasms 20Esophageal Neoplasms 20Liver Neoplasms 18Head and Neck Neoplasms 18Disease 18Wilms Tumor 17Carcinoma, Hepatocellular 17Endometrial Neoplasms 16Sarcoma 15Prostatic Hyperplasia 15

Interventions

Docetaxel 2Sunitinib 1Prednisone 1PE regimen 1Injections 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Hormone Refractory Prostate Cancer × Genitourinary × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

NCT00795171 2010-08-18

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer

Medical University of Vienna

Phase 2 Unknown
60 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡